- Home
- LIPO vs XRTX Comparison
LIPO vs XRTX Comparison
Compare LIPO & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- XRTX
- Stock Information
- Founded
- LIPO 2005
- XRTX 2011
- Country
- LIPO United States
- XRTX Canada
- Employees
- LIPO N/A
- XRTX N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- LIPO Health Care
- XRTX Health Care
- Exchange
- LIPO Nasdaq
- XRTX Nasdaq
- Market Cap
- LIPO 3.1M
- XRTX 3.0M
- IPO Year
- LIPO 2022
- XRTX N/A
- Fundamental
- Price
- LIPO $3.14
- XRTX $0.82
- Analyst Decision
- LIPO Strong Buy
- XRTX
- Analyst Count
- LIPO 1
- XRTX 0
- Target Price
- LIPO $16.00
- XRTX N/A
- AVG Volume (30 Days)
- LIPO 6.6M
- XRTX 45.7K
- Earning Date
- LIPO 02-28-2025
- XRTX 11-15-2024
- Dividend Yield
- LIPO N/A
- XRTX N/A
- EPS Growth
- LIPO N/A
- XRTX N/A
- EPS
- LIPO N/A
- XRTX N/A
- Revenue
- LIPO $483,533.00
- XRTX N/A
- Revenue This Year
- LIPO N/A
- XRTX N/A
- Revenue Next Year
- LIPO N/A
- XRTX N/A
- P/E Ratio
- LIPO N/A
- XRTX N/A
- Revenue Growth
- LIPO 0.78
- XRTX N/A
- 52 Week Low
- LIPO $2.21
- XRTX $0.82
- 52 Week High
- LIPO $12.00
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- LIPO 48.05
- XRTX 34.99
- Support Level
- LIPO $3.35
- XRTX $0.87
- Resistance Level
- LIPO $4.69
- XRTX $0.97
- Average True Range (ATR)
- LIPO 0.62
- XRTX 0.07
- MACD
- LIPO -0.02
- XRTX 0.00
- Stochastic Oscillator
- LIPO 13.31
- XRTX 0.00
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.